Goldline Pharmaceutical shares made a strong debut on BSE SME today, opening at ₹59.75, which is 40% higher than the issue price of ₹43. However, the stock was locked in at a 5% lower circuit at ₹56.77 per share after touching an intraday high of ₹60 per share. The IPO, which closed on May 14, demonstrated exceptional investor interest with 600.53 times oversubscription by day 3. The company's shares are now trading at a premium to the issue price, reflecting strong market confidence in the pharmaceutical company.
The IPO demonstrated exceptional investor interest with 600.53 times oversubscription during the third day of bidding, as reported by chittorgarh.com. The strong subscription numbers indicate significant market confidence in Goldline Pharmaceutical Ltd. The IPO's retail investors' portion was fully subscribed, while non-institutional investors' quota received 1.99 times subscription. The qualified institutional buyers (QIBs) portion was booked, with the overall IPO achieving 1.99 times subscription across all categories. Applicants who did not receive any shares will initiate the refund process, while those who received shares will have their accounts credited on Monday, 18 May.
Goldline Pharmaceutical operates on an asset-light pharmaceutical model, where the company does not manufacture products itself but works with third-party contract manufacturers while focusing on branding, marketing, and distribution. According to latest financial data, the company achieved revenue growth from ₹19.8 crore in FY23 to ₹28 crore in FY25, while profits jumped significantly from ₹25 lakh to ₹2.8 crore in just two years. Established in 2004, the company specialises in pharmaceutical marketing across five primary segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. To ensure reliable supply chain and steady market presence, the company currently collaborates with 15 manufacturers and 8 distributors under contractual agreements.
The Goldline Pharmaceutical IPO is valued at ₹11.61 crore through a book-building method, consisting entirely of a fresh issuance of 27 lakh shares. The primary purpose of the IPO is to settle ₹8.35 crore in loans, with the remaining funds designated for general corporate purposes. As of March 2026, the company had total debt of ₹9.13 crore. The IPO opened for subscription on Tuesday, 12 May, and closed on Thursday, 14 May, with investors able to apply for a minimum lot size of 3,000 equity shares in multiples of 3,000 shares. Cumulative Capital Pvt. Ltd serves as the book-running lead manager, while Bigshare Services Pvt. Ltd acts as the registrar.
The Goldline Pharmaceutical IPO GMP stands at ₹15 per share, indicating strong grey market activity. According to expert analysis, considering the upper end of the IPO price band and current grey-market premium, the estimated listing price is ₹58 per share, which is 34.88% lower than the IPO price of ₹43. The Goldline Pharmaceutical IPO listing is scheduled for Tuesday, 19 May on BSE SME, as reported by LiveMint. The refund procedure will also begin on Monday, 18 May. The listing date provides investors with a clear timeline for when they can expect to trade their allocated shares in the secondary market.
